Latest news with #INBS
Yahoo
07-08-2025
- Business
- Yahoo
EXCLUSIVE: Intelligent Bio Expects Double Digit Topline Growth In Q4
Intelligent Bio Solutions Inc. (NASDAQ:INBS) reported preliminary fiscal fourth quarter revenue results and selected operational highlights on Thursday. Intelligent Bio Solutions is a medical technology company delivering intelligent, rapid, noninvasive testing solutions. 'Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth,' said Harry Simeonidis, President and CEO at Intelligent Bio company expects to report fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year‑over‑year, reflecting continued demand for its higher‑margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over the fiscal third and second quarters. Operational Highlights Intelligent Bio submitted the FDA 510(k) application for its opiate test system for codeine, supported by new scientific and clinical validation data. In July, the company announced the collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission. View more earnings on INBS Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System, supporting broader global adoption. Launched localized websites and enhanced CRM workflows to improve partner and end-user engagement across Europe, the Middle East, and Latin America. Intelligent Bio reported a third-quarter 2025 loss of 44 cents per share, down from a loss of $1.43 a year ago. The noninvasive testing solutions provider reported third quarter sales of $728.87 thousand, down from $823.80 thousand a year ago. Price Action: At the last check Thursday, INBS stock was up 2.56% at $1.60 during the premarket session. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Intelligent Bio Expects Double Digit Topline Growth In Q4 originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Irish Times
29-07-2025
- Business
- Irish Times
Disqualification and €130,000 fine for former Irish Nationwide finance director confirmed
The High Court has confirmed a Central Bank inquiry decision fining Irish Nationwide Building Society's former finance director John Stanley Purcell €130,000 for his role in regulatory breaches at the lender before its collapse during the financial crisis. The president of the High Court , Mr Justice David Barniville, also confirmed the inquiry's decision to reprimand Mr Purcell; disqualify him for four years from company involvement and to order that he and the bank pay their own legal costs related to the inquiry. The sanctions were decided upon following the long-running inquiry by the Central Bank of Ireland (CBI), which cost more than €24.3m, into the conduct of INBS' affairs. Under the relevant law, the sanctions only come into effect if confirmed by the High Court. READ MORE [ Fifteen years, €24.3m and 1,384 pages later, was the Irish Nationwide inquiry really worth it? Opens in new window ] When seeking that confirmation on Tuesday, barrister Shelley Horan, for the CBI, said Mr Purcell had agreed to the application proceeding in his absence. Mr Purcell did not intend to appeal the inquiry findings concerning him and accepted the content of the sanctions decision but had suggested a fine of €100,000, counsel said. After the inquiry panel decided a €130,000 fine was appropriate, Mr Purcell said he would pay that within 14 days of confirmation, counsel said. In his ruling, Mr Justice Barniville noted the Central Bank Act provided, where there is no appeal or challenge to an inquiry decision, the court 'shall' confirm the decision and proposed sanction unless it involved a manifest and fundamental error of law or disproportionality. The Central Bank inquiry looked into seven sets of alleged regulatory breaches between July 2006 and September 2008, including that INBS allegedly failed to process loans in line with its own policies and to obtain property security for commercial loans. Between 2008 and 2010, INBS suffered financial losses in excess of €6 billion, primarily arising from the impairment of its commercial loan book. INBS cost taxpayers €5.4 billion to rescue during the financial crisis before its remains were folded in 2011 into IBRC, previously Anglo Irish Bank. The inquiry found, between 2004 and 2008, Mr Purcell, as a board member of INBS, participated in breaches of financial services law by the lender relating to its commercial lending. The report of the inquiry was provided to Mr Purcell and the bank's enforcement section in April 2024 and a hearing last October heard submissions before deciding on sanctions. On Tuesday, having considered the evidence and the law, Mr Justice Barniville said he was satisfied the court was required to make the confirmation orders sought. The sanctions decision seemed 'wholly proportionate' to the findings made and was not disputed by the bank or Mr Purcell who had adopted a 'reasonable' and 'sensible' approach. Mr Purcell was among five INBS directors originally subject to the Central Bank inquiry when it was established in 2015. After public hearings started in late 2017, the bank reached settlement agreements with three of the original five – former INBS chairman Michael Walsh; one-time head of commercial lending Tom McMenamin; and former head of UK commercial lending Gary McCollum. They were fined a total of €243,000, with the largest amount paid by Mr McCollum. It dropped its case against the failed lender's former long-standing managing director, Michael Fingleton , now aged 86, in December 2019, due to his health issues. The High Court is currently hearing a civil case brought against Mr Fingleton by the Irish Bank Resolution Corporation (IBRC), which took over INBS's assets in 2011, for alleged negligent mismanagement of the lender. He is not in a position to give evidence in that case.
Globe and Mail
20-06-2025
- Business
- Globe and Mail
Intelligent Bio Solutions (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste management provider, will implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations. Covering over 20 remote land clearing and green waste sites, this marks MWS's first shift to in-house, on-site drug testing for pre-employment, random, and for-cause purposes. The fingerprint-based system delivers non-invasive results in under ten minutes, enabling rapid safety decisions without disrupting field operations. INBS continues to expand its reach into safety-critical industries, with its scalable, sweat-based drug testing now in use by over 450 organizations across 24 countries. To view the full article, visit About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN
Yahoo
18-06-2025
- Business
- Yahoo
EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced that Managed Waste Service plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites. Managed Waste Service is an Australia-based waste management provider. The decision marks Managed Waste Service's first move into in-house drug testing across multiple locations. More than 20 sites are engaged in remote testing operations. Managed Waste Service plans to conduct pre-employment, random, and for-cause testing on-site, giving operational teams complete control over safety processes without the disruption associated with traditional outsourced Intelligent Fingerprinting Drug Screening System offers a quick, noninvasive method of screening for recent drug use through fingerprint sweat analysis, delivering results in under ten minutes. Intelligent Bio Solutions' technology enables Managed Waste Service to implement a scalable, portable solution that aligns with the nature of their fieldwork, whether testing at a remote clearing site or managing compliance across several waste facilities simultaneously. This implementation reflects Intelligent Bio Solutions' continued expansion into safety-critical industries, with environmental services now joining a growing portfolio of sectors adopting sweat-based drug testing. Intelligent Bio Solutions provides drug testing. Over 450 organizations in 24 countries use its technology to streamline and simplify workplace testing. In June, SMARTOX, a U.S.-based provider of drug and alcohol testing products and services, said it deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including over 1,500 tests in 2024 alone. As adoption grows in the U.S. Forensic Use Only market, Intelligent Bio continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology. Price Action: INBS stock is up 1.55% at $1.96 during the premarket session at the last check on Wednesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
16-06-2025
- Business
- Yahoo
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
Intelligent Bio Solutions INBS recently expanded its U.S. forensic market presence through a strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. The company's breakthrough technology enables non-invasive drug detection using fingerprint sweat, delivering results in under 10 minutes for substances like opiates, cocaine, methamphetamine, and cannabis. The collaboration with SMARTOX is expected to accelerate INBS's penetration into high-need forensic and law enforcement environments while streamlining testing processes with greater hygiene and operational efficiency. With FDA 510(k) clearance for its opiate test system underway, INBS is positioning itself to expand into broader markets, including workplace drug testing. This move reflects the company's strategic push to innovate drug screening while scaling its footprint across the United States and beyond. Following the announcement, shares of the company closed flat at $1.91 on Friday. However, in the year-to-date period, INBS's shares have gained 36.4% compared with the industry's 2.6% growth. The S&P 500 increased 1.1% in the same time frame. The SMARTOX partnership positions INBS for long-term growth by accelerating the adoption of its fingerprint drug screening technology across U.S. forensic and rehabilitation settings. With SMARTOX's strong distribution network and credibility in toxicology, INBS gains access to a broader customer base and faster deployment channels. This not only enhances recurring test volume but also strengthens its case for FDA clearance and future expansion into high-margin markets like workplace and clinical testing, unlocking significant commercial scalability over time. Meanwhile, INBS currently has a market capitalization of $13.2 million. INBS expects 80.4% growth in its earnings for 2025. Image Source: Zacks Investment Research Intelligent Bio Solutions' strategic partnership with SMARTOX marks a significant milestone in its U.S. expansion strategy, particularly within forensic and rehabilitation drug testing markets. SMARTOX, a well-established name in toxicology with a global distribution network, has already facilitated the deployment of over 50 Intelligent Fingerprinting Drug Screening Readers across drug courts, correctional facilities, and rehab centers in the United States, resulting in over 7,000 tests performed to date. This collaboration not only enhances INBS's market credibility but also enables rapid scaling through SMARTOX's access to public-sector institutions and specialized customer bases. Complementing this commercial momentum, INBS is actively pursuing FDA 510(k) clearance for its opiate (codeine) fingerprint drug test system. This regulatory milestone, once achieved, will allow INBS to formally enter high-value markets like workplace safety, clinical diagnostics, and broader public health initiatives. FDA clearance would not only validate the efficacy and safety of INBS's unique non-invasive testing method but also serve as a powerful differentiator against traditional urine or saliva-based systems. Per a report by MarketsandMarkets, the global drug screening market, valued at $9.1 billion in 2024, is forecasted to grow at a robust CAGR of 16.6%, reaching $19.5 billion by 2029. Growth of the drug screening market is driven by the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing. INBS carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Intelligent Bio Solutions Inc. (INBS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
